PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 34395553-8 2021 PAD4 inhibitor YW3-56 inhibited Ang II-induced NET formation. YW3-56 15-21 MMTV LTR integration site 4 Mus musculus 0-4 34349829-7 2021 Therefore, we first detected the expression of PAD4 in EPCs of peripheral arterial disease and detected changes in the number and function of endothelial progenitor cells in peripheral blood after injecting the PAD4 inhibitor Cl-amidine into mice. N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide 226-236 MMTV LTR integration site 4 Mus musculus 47-51 34349829-7 2021 Therefore, we first detected the expression of PAD4 in EPCs of peripheral arterial disease and detected changes in the number and function of endothelial progenitor cells in peripheral blood after injecting the PAD4 inhibitor Cl-amidine into mice. N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide 226-236 MMTV LTR integration site 4 Mus musculus 211-215 34349829-9 2021 The results show that PAD4 is highly expressed in peripheral arterial diseases and the PAD4 inhibitor Cl-amidine can increase the number of EPCs and can treat peripheral arterial diseases by improving the proliferation, migration, and vascularization of EPCs. N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide 102-112 MMTV LTR integration site 4 Mus musculus 22-26 34349829-9 2021 The results show that PAD4 is highly expressed in peripheral arterial diseases and the PAD4 inhibitor Cl-amidine can increase the number of EPCs and can treat peripheral arterial diseases by improving the proliferation, migration, and vascularization of EPCs. N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide 102-112 MMTV LTR integration site 4 Mus musculus 87-91 34260389-6 2021 In vitro, ATP, the main neutrophil agonist present at the site of laser-induced injury, induced the overexpression of PAD4 and CitH3 but not NETosis. Adenosine Triphosphate 10-13 MMTV LTR integration site 4 Mus musculus 118-122 34248948-6 2021 Furthermore, a Syk inhibitor attenuated NETs, that activated by phorbol myristate acetate (PMA; a NETs activator) or lipopolysaccharide (LPS; a potent inflammatory stimulator), more prominently in Fcgr2b-/- neutrophils than the WT cells as determined by dsDNA, PAD4 and MPO. Tetradecanoylphorbol Acetate 64-89 MMTV LTR integration site 4 Mus musculus 261-265 34248948-7 2021 In addition, the inhibitors against Syk and PAD4 attenuated lupus characteristics (serum creatinine, proteinuria, and anti-dsDNA) in Fcgr2b-/- mice at 120 h post-renal I/R injury. Creatinine 89-99 MMTV LTR integration site 4 Mus musculus 44-48 35222675-22 2022 The immunohistochemistry assays also showed decreased expression levels of NE, MPO, PAD4, and CitH3 induced by tetrandrine in comparison with the AA group (P < 0.01). tetrandrine 111-122 MMTV LTR integration site 4 Mus musculus 84-88 35140112-7 2022 RESULTS: In contrast to NPM regulation, which is mediated by peptidylarginine deiminase (PAD4) citrullination of arginine at position 197, only citrullinated NPM266-285 peptide induced a citrulline-specific CD4 T cell response in transgenic mice models expressing human HLA-DP4 or HLA-DR4. Citrulline 187-197 MMTV LTR integration site 4 Mus musculus 89-93 35185885-6 2022 Mice which had myeloid-specific deletion of PAD4 were generated and treated with pristane to assess the involvement of PAD4 and PAD4-dependent NET formation in pristane-induced lung inflammation. pristane 160-168 MMTV LTR integration site 4 Mus musculus 128-132 35185885-7 2022 Specific deletion of PAD4 in myeloid cells resulted in decreased expression of ER stress genes in the pristane model, with accompanying reduction in IFN-driven genes and pathology. pristane 102-110 MMTV LTR integration site 4 Mus musculus 21-25 34114683-11 2022 CLP-induced PAD4 levels, histone 3 citrullination, edema, MPO activity, and neutrophil recruitment in the lung were markedly reduced in the mice lacking miR-155. 6-carboxypterin 0-3 MMTV LTR integration site 4 Mus musculus 12-16 33751034-10 2021 Delivery of the PAD4 inhibitor GSK484 reduced NET accumulation at sites of intimal injury and preserved endothelial continuity. GSK484 31-37 MMTV LTR integration site 4 Mus musculus 16-20 34019862-0 2021 Bongkrekic acid induced neutrophil extracellular traps via p38, ERK, PAD4, and P2X1-mediated signaling. Bongkrekic Acid 0-15 MMTV LTR integration site 4 Mus musculus 69-73 33380498-6 2021 Efferocytosis in the peritoneal cavity of rmCIRP-injected PAD4-/- mice was higher than WT mice. rmcirp 42-48 MMTV LTR integration site 4 Mus musculus 58-62 33289753-11 2021 Further investigation showed that the quantitation of NETs was markedly decreased by the inhibitors of reactive oxygen species (ROS)-derived-NADPH oxidase, ERK1/2, p38, Rac and PAD4 signaling pathways, indicating the crucial role of these signaling pathways in beta-conglycinin-induced NETs. Reactive Oxygen Species 103-126 MMTV LTR integration site 4 Mus musculus 177-181 33289753-11 2021 Further investigation showed that the quantitation of NETs was markedly decreased by the inhibitors of reactive oxygen species (ROS)-derived-NADPH oxidase, ERK1/2, p38, Rac and PAD4 signaling pathways, indicating the crucial role of these signaling pathways in beta-conglycinin-induced NETs. Reactive Oxygen Species 128-131 MMTV LTR integration site 4 Mus musculus 177-181 32437924-8 2020 HCQ inhibited PAD4 and Rac2 expressions by blocking TLR9. Hydroxychloroquine 0-3 MMTV LTR integration site 4 Mus musculus 14-18 32915635-0 2020 PAD4 Deficiency Improves Bleomycin-induced Neutrophil Extracellular Traps and Fibrosis in Mouse Lung. Bleomycin 25-34 MMTV LTR integration site 4 Mus musculus 0-4 31519688-8 2019 PAD4-KO tumors had decreased mitochondrial density, mitochondrial DNA, a lesser degree of ATP production, along with significantly decreased mitochondrial biogenesis proteins PGC1alpha, TFAM, and NRF-1. Adenosine Triphosphate 90-93 MMTV LTR integration site 4 Mus musculus 0-4 32427405-0 2020 Kaempferol blocks neutrophil extracellular traps formation and reduces tumour metastasis by inhibiting ROS-PAD4 pathway. kaempferol 0-10 MMTV LTR integration site 4 Mus musculus 107-111 32427405-0 2020 Kaempferol blocks neutrophil extracellular traps formation and reduces tumour metastasis by inhibiting ROS-PAD4 pathway. ros 103-106 MMTV LTR integration site 4 Mus musculus 107-111 32193354-1 2020 Peptidyl arginine deiminase 4 (PAD4/PADI4) is a posttranslational modification enzyme that converts protein arginine or mono-methylarginine to citrulline. Arginine 9-17 MMTV LTR integration site 4 Mus musculus 31-35 32193354-1 2020 Peptidyl arginine deiminase 4 (PAD4/PADI4) is a posttranslational modification enzyme that converts protein arginine or mono-methylarginine to citrulline. mono-methylarginine 120-139 MMTV LTR integration site 4 Mus musculus 31-35 32193354-1 2020 Peptidyl arginine deiminase 4 (PAD4/PADI4) is a posttranslational modification enzyme that converts protein arginine or mono-methylarginine to citrulline. Citrulline 143-153 MMTV LTR integration site 4 Mus musculus 31-35 29981294-4 2018 Here, we showed that treatment with YW3-56, a PAD2/PAD4 inhibitor, significantly diminished PAD activation, blocked LPS-induced pulmonary vascular leakage, alleviated acute lung injury, and improved survival in a mouse model of lethal LPS-induced endotoxemia. YW3-56 36-42 MMTV LTR integration site 4 Mus musculus 51-55 31248335-12 2019 Next, we assessed the effect of extracellular PAD4 on platelet-plug formation after ferric chloride-induced injury of mesenteric venules. ferric chloride 84-99 MMTV LTR integration site 4 Mus musculus 46-50 29896200-6 2018 Using an antibody to citrullinated histone 3 (H3Cit) as an indicator of PAD4 activity, we show that beta-glucan stimulated NETosis occurs in neutrophils from C57BL/6, but not PAD4-/- mice. beta-Glucans 100-111 MMTV LTR integration site 4 Mus musculus 72-76 28400047-5 2017 In other experiments, the PAD4 inhibitor streptonigrin was injected intravitreally into injured eyes ex vivo to test inhibitory activity in an organ culture system. Streptonigrin 41-54 MMTV LTR integration site 4 Mus musculus 26-30 28128853-2 2017 This present study was undertaken to explore the efficacy of a novel PAD4-selective inhibitor, GSK199, in the murine collagen-induced arthritis model of rheumatoid arthritis. GSK199 95-101 MMTV LTR integration site 4 Mus musculus 69-73 29263862-7 2017 Further studies in PAD4-/- mice confirmed a significant role for neutrophil extracellular trap formation in the adjuvant activity of Alum. aluminum sulfate 133-137 MMTV LTR integration site 4 Mus musculus 19-23 27312847-6 2016 Nicotine-induced NET formation is mediated via nicotine acetylcholine receptors, depends on Akt and PAD4 activation, but is Nox2-independent, as demonstrated by pharmacological inhibition of Nox2 and by use of Nox2-deficient mouse neutrophils. Nicotine 0-8 MMTV LTR integration site 4 Mus musculus 100-104 29318161-7 2017 LPS, ATP, and TNF triggered PAD2 and PAD4 expression; in contrast, no expression was detected in the control group (p < 0.001). Adenosine Triphosphate 5-8 MMTV LTR integration site 4 Mus musculus 37-41 25622091-2 2015 New selective PAD4 inhibitors binding a calcium-deficient form of the PAD4 enzyme have validated the critical enzymatic role of human and mouse PAD4 in both histone citrullination and neutrophil extracellular trap formation for, to our knowledge, the first time. Calcium 40-47 MMTV LTR integration site 4 Mus musculus 70-74 26740598-11 2016 PAD4 inhibition by Cl-amidine reduced NETting neutrophils and rescued wound healing in diabetic mice. N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide 19-29 MMTV LTR integration site 4 Mus musculus 0-4 25164081-1 2014 Peptidyl arginine deiminase (PAD)4 is a nuclear enzyme that catalyzes the posttranslational conversion of arginine residues to citrulline. Citrulline 127-137 MMTV LTR integration site 4 Mus musculus 0-34 25164081-6 2014 In contrast, mice pretreated with PAD4 inhibitors (2-chloroamidine or streptonigrin) had significantly reduced renal I/R injury. 2-chloroamidine 51-66 MMTV LTR integration site 4 Mus musculus 34-38 25164081-6 2014 In contrast, mice pretreated with PAD4 inhibitors (2-chloroamidine or streptonigrin) had significantly reduced renal I/R injury. Streptonigrin 70-83 MMTV LTR integration site 4 Mus musculus 34-38 34881329-14 2021 Administration of nintedanib reduced the expression of Pad4 and citrullinated peptides and eliminated invasive epithelial cells. nintedanib 18-28 MMTV LTR integration site 4 Mus musculus 55-59 23637922-5 2013 We hypothesized that the delivery of a stable immunogenic domain 4 of protective antigen (PAD4) of Bacillus anthracis encapsulated in a poly (lactide-co-glycolide) (PLGA)--an FDA approved biocompatible and biodegradable material, may alleviate the problems of booster dose, adjuvant toxicity and stability associated with anthrax vaccines. Polyglactin 910 136-163 MMTV LTR integration site 4 Mus musculus 90-94 23637922-6 2013 We made a PLGA based protective antigen domain 4 nanoparticle (PAD4-NP) formulation using water/oil/water solvent evaporation method. Water 90-95 MMTV LTR integration site 4 Mus musculus 63-67 23637922-6 2013 We made a PLGA based protective antigen domain 4 nanoparticle (PAD4-NP) formulation using water/oil/water solvent evaporation method. Oils 96-99 MMTV LTR integration site 4 Mus musculus 63-67 23637922-6 2013 We made a PLGA based protective antigen domain 4 nanoparticle (PAD4-NP) formulation using water/oil/water solvent evaporation method. Water 100-105 MMTV LTR integration site 4 Mus musculus 63-67 23833800-6 2010 The PAD4 HTS campaign identified the natural product streptonigrin (SID 11532976) as an irreversible PAD4-specific inhibitor. Streptonigrin 53-66 MMTV LTR integration site 4 Mus musculus 4-8 23833800-6 2010 The PAD4 HTS campaign identified the natural product streptonigrin (SID 11532976) as an irreversible PAD4-specific inhibitor. Streptonigrin 53-66 MMTV LTR integration site 4 Mus musculus 101-105 19093029-3 2008 Deimination, the conversion of protein-bound arginine to citrulline, is mediated by the peptidylarginine deiminase (PAD) family of enzymes, of which the PAD2 and PAD4 isoforms are present in myelin. Arginine 45-53 MMTV LTR integration site 4 Mus musculus 162-166 19093029-3 2008 Deimination, the conversion of protein-bound arginine to citrulline, is mediated by the peptidylarginine deiminase (PAD) family of enzymes, of which the PAD2 and PAD4 isoforms are present in myelin. Citrulline 57-67 MMTV LTR integration site 4 Mus musculus 162-166 34363921-14 2021 The blockade of NETs in vivo using PAD4-/- mice or DNase I treatment reduces the activity of Tregs. tregs 93-98 MMTV LTR integration site 4 Mus musculus 35-39